Indusatumab vedotin
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Guanylate cyclase 2C |
| Clinical data | |
| Other names | MLN-0264, 5F9vcMMAE |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| Chemical and physical data | |
| Molar mass | ~150 kg/mol |
Indusatumab vedotin (MLN-0264) is an antibody-drug conjugate that is under development for the treatment of pancreatic cancer[1] and other gastrointestinal cancers.[2] It consists of a monoclonal antibody (indusatumab) that targets the enzyme guanylate cyclase 2C which is present in some cancers, linked to an average of three to four molecules of the chemotherapeutic agent monomethyl auristatin E (MMAE).[3]
It is in Phase II clinical trials as of February 2016[update].[1][2]
References
- ^ a b Clinical trial number NCT02202785 for "A Study of MLN0264 in Patients With Pancreatic Cancer" at ClinicalTrials.gov
- ^ a b Clinical trial number NCT02202759 for "A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction" at ClinicalTrials.gov
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 74" (PDF). WHO Drug Information. 29 (3): 402–3. 2015.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |